Page last updated: 2024-12-07

glucosamine 6-phosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

glucosamine 6-phosphate: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID439217
CHEBI ID15873
SCHEMBL ID4363568
MeSH IDM0041398

Synonyms (16)

Synonym
alpha-d-glucosamine 6-(dihydrogen phosphate)
glucosamine 6-phosphate
2-amino-2-deoxy-6-o-phosphono-alpha-d-glucopyranose
2-amino-2-deoxy-alpha-d-glucopyranose 6-(dihydrogen phosphate)
CHEBI:15873
d-glucosamine phosphate
1MOQ
DB02657
BMSE000189
glcn-6-p
SCHEMBL4363568
{[(2r,3s,4r,5r,6s)-5-amino-3,4,6-trihydroxyoxan-2-yl]methoxy}phosphonic acid
glucose 6-phosphorate
glucose-6-phosphorate
XHMJOUIAFHJHBW-UKFBFLRUSA-N
Q55168356
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-amino-2-deoxy-D-glucopyranose 6-phosphateThe pyranose form of D-glucosamine 6-phosphate.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (54)

PathwayProteinsCompounds
Glycolysis6132
Metabolism14961108
Carbohydrate metabolism173120
Glucose metabolism7642
Glutamate Metabolism2244
Amino Sugar Metabolism1731
4-Hydroxybutyric Aciduria/Succinic Semialdehyde Dehydrogenase Deficiency2244
Homocarnosinosis2244
Hyperinsulinism-Hyperammonemia Syndrome2244
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
2-Hydroxyglutric Aciduria (D and L Form)2244
Tay-Sachs Disease1731
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Succinic Semialdehyde Dehydrogenase Deficiency2244
Lipopolysaccharide Biosynthesis4153
Amino Sugar and Nucleotide Sugar Metabolism I1733
Amino Sugar and Nucleotide Sugar Metabolism II2231
Amino Sugar and Nucleotide Sugar Metabolism III2340
Peptidoglycan Biosynthesis I3036
Metabolism of proteins1058144
Lipopolysaccharide Biosynthesis II4053
N-Acetylneuraminate, N-Acetylmannosamine, and N-Acetylglucosamine Degradation613
Lipopolysaccharide Biosynthesis III3352
Peptidoglycan Biosynthesis II3037
Amino Sugar and Nucleotide Sugar Metabolism2229
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein5068
Synthesis of substrates in N-glycan biosythesis3756
Synthesis of UDP-N-acetyl-glucosamine617
UDP-N-acetyl-D-glucosamine biosynthesis II916
Chitin Biosynthesis921
CMP-legionaminate biosynthesis I1026
chitin biosynthesis1640
ammonia assimilation cycle III433
L-glutamine biosynthesis I725
superpathway of mycolyl-arabinogalactan-peptidoglycan complex biosynthesis2257
N-acetylglucosamine degradation I59
N-acetylglucosamine degradation II713
O-antigen building blocks biosynthesis (E. coli)950
anhydromuropeptides recycling I1348
chitin derivatives degradation321
chitin degradation I (archaea)514
superpathway of N-acetylglucosamine, N-acetylmannosamine and N-acetylneuraminate degradation924
L-glutamate and L-glutamine biosynthesis1442
superpathway of N-acetylneuraminate degradation3979
UDP-N-acetyl-D-glucosamine biosynthesis II2333
UDP-N-acetyl-D-glucosamine biosynthesis I735
UDP-N-acetyl-D-galactosamine biosynthesis II724
UDP-N-acetyl-D-galactosamine biosynthesis III415
superpathway of UDP-N-acetylglucosamine-derived O-antigen building blocks biosynthesis2461
UDP-N-acetylglucosamine biosynthesis412
anhydromuropeptides recycling026
Biochemical pathways: part I0466
UDP-N-acetylgalactosamine biosynthesis112

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Glucosamine 6-phosphate SynthaseEscherichia coliKi350.0000350.0000350.0000350.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1811Experimentally measured binding affinity data derived from PDB1998Structure (London, England : 1993), Aug-15, Volume: 6, Issue:8
Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: evidence from a 1.6 A crystal structure of the isomerase domain.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1998Structure (London, England : 1993), Aug-15, Volume: 6, Issue:8
Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: evidence from a 1.6 A crystal structure of the isomerase domain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (123)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (17.07)18.7374
1990's11 (8.94)18.2507
2000's36 (29.27)29.6817
2010's52 (42.28)24.3611
2020's3 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.42%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other121 (97.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]